András Málnási-Csizmadia

András Málnási-Csizmadia

Auto-generated profile, based on publicly available information

András Málnási-Csizmadia

Department of Biochemistry, Eötvös Loránd University, Budapest, Hungary

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MKMihály Kovács
Mihály Kovács
JTJudit Tóth
Judit Tóth
Csaba HetényiCsaba Hetényi
Csaba Hetényi
AMAndrás Málnási-Csizmadia
András Málnási-Csizmadia
JSJames R. Sellers
James R. Sellers
Blebbistatin is a recently discovered small molecule inhibitor showing high affinity and selectivity toward myosin II. Here we report a detailed investigation of its mechanism of inhibition. Blebbistatin does not compete with nucleotide binding to the skeletal muscle myosin subfragment-1. The inhibitor preferentially binds to the ATPase intermediate with ADP and phosphate bound at the active site, and it slows down phosphate release. Blebbistatin interferes neither with binding of myosin to actin nor with ATP-induced actomyosin dissociation. Instead, it blocks the myosin heads in a products complex with low actin affinity. Blind docking molecular simulations indicate that the productive blebbistatin-binding site of the myosin head is within the aqueous cavity between the nucleotide pocket and the cleft of the actin-binding interface. The property that blebbistatin blocks myosin II in an actin-detached state makes the compound useful both in muscle physiology and in exploring the cellular function of cytoplasmic myosin II isoforms, whereas the stabilization of a specific myosin intermediate confers a great potential in structural studies.

29 February 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BGB. Green
B. Green
SKS. Kovalev
S. Kovalev
VAV. Asgekar
V. Asgekar
GGG. Geloni
G. Geloni
ULU. Lehnert
U. Lehnert
MGM. Gensch
M. Gensch
Ultrashort flashes of THz light with low photon energies of a few meV, but strong electric or magnetic field transients have recently been employed to prepare various fascinating nonequilibrium states in matter. Here we present a new class of sources based on superradiant enhancement of radiation from relativistic electron bunches in a compact electron accelerator that we believe will revolutionize experiments in this field. Our prototype source generates high-field THz pulses at unprecedented quasi-continuous-wave repetition rates up to the MHz regime. We demonstrate parameters that exceed state-of-the-art laser-based sources by more than 2 orders of magnitude. The peak fields and the repetition rates are highly scalable and once fully operational this type of sources will routinely provide 1 MV/cm electric fields and 0.3 T magnetic fields at repetition rates of few 100 kHz. We benchmark the unique properties by performing a resonant coherent THz control experiment with few 10 fs resolution.

20 June 2014 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
MKMiklós Képiró
Miklós Képiró
BVBoglárka H. Várkuti
Boglárka H. Várkuti
LVLászló Végner
László Végner
GVGergely Vörös
Gergely Vörös
GHGyörgy Hegyi
György Hegyi
AMAndrás Málnási‐Csizmadia
András Málnási‐Csizmadia

31 May 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BVBoglárka H. Várkuti
Boglárka H. Várkuti
MKMiklós Képiró
Miklós Képiró
IHIstván Ádám Horváth
István Ádám Horváth
LVLászló Végner
László Végner
SRSzilvia Ráti
Szilvia Ráti
AMAndrás Málnási-Csizmadia
András Málnási-Csizmadia
Blebbistatin is a commonly used molecular tool for the specific inhibition of various myosin II isoforms both in vitro and in vivo. Despite its popularity, the use of blebbistatin is hindered by its poor water-solubility (below 10 micromolar in aqueous buffer) and blue-light sensitivity, resulting in the photoconversion of the molecule, causing severe cellular phototoxicity in addition to its cytotoxicity. Furthermore, blebbistatin forms insoluble aggregates in water-based media above 10 micromolar with extremely high fluorescence and also high adherence to different types of surfaces, which biases its experimental usage. Here, we report a highly soluble (440 micromolar in aqueous buffer), non-fluorescent and photostable C15 amino-substituted derivative of blebbistatin, called para-aminoblebbistatin. Importantly, it is neither photo- nor cytotoxic, as demonstrated on HeLa cells and zebrafish embryos. Additionally, para-aminoblebbistatin bears similar myosin II inhibitory properties to blebbistatin or para-nitroblebbistatin (not to be confused with the C7 substituted nitroblebbistatin), tested on rabbit skeletal muscle myosin S1 and on M2 and HeLa cells. Due to its drastically improved solubility and photochemical feature, as well as lack of photo- or cytotoxicity, para-aminoblebbistatin may become a feasible replacement for blebbistatin, especially at applications when high concentrations of the inhibitor or blue light irradiation is required.

1 September 2018 in Trends in Biochemical Sciences
Verified
Journal Article
Closed access
ARAnna Á. Rauscher
Anna Á. Rauscher
MGMáté Gyimesi
Máté Gyimesi
MKMihály Kovács
Mihály Kovács
AMAndrás Málnási-Csizmadia
András Málnási-Csizmadia

28 September 2001 in Biochemistry
Verified
Journal Article
Closed access
AMAndrás Málnási-Csizmadia
András Málnási-Csizmadia
DPDavid S. Pearson
David S. Pearson
MKMihály Kovács
Mihály Kovács
RWRobert J. Woolley
Robert J. Woolley
MGMichael A. Geeves
Michael A. Geeves
CBClive R. Bagshaw
Clive R. Bagshaw